Diabetes, Vol 44, Issue 9 1087-1092, Copyright © 1995 by American Diabetes Association

ARTICLES

Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling

PW Young, MA Cawthorne, PJ Coyle, JC Holder, GD Holman, IJ Kozka, DM Kirkham, CA Lister and SA Smith
SmithKline Beecham Pharmaceuticals, Epsom, Surrey, U.K.

(+/-)-5-([4-[2-Methyl-2(pyridylamino)ethoxy]phenyl]methyl) 2,4-thiazolidinedione (BRL 49653) is a new potent antidiabetic agent that improves insulin sensitivity in animal models of NIDDM. In C57BL/6 obese (ob/ob) mice, BRL 49653, included in the diet for 8 days, improved glucose tolerance. The half-maximal effective dose was 3 mumol/kg diet, which is equivalent to approximately 0.1 mg/kg body wt. Improvements in glucose tolerance were accompanied by significant reductions in circulating triacylglycerol, nonesterified fatty acids, and insulin. The insulin receptor number of epididymal white adipocytes prepared from obese mice treated with BRL 49653 (30 mumol/kg diet) for 14 days was increased twofold. The affinity of the receptor for insulin was unchanged. In the absence of added insulin, the rates of glucose transport in adipocytes from untreated and BRL 49653-treated obese mice were similar. Insulin (73 nmol/l) produced only a 1.5-fold increase in glucose transport in adipocytes from control obese mice, whereas after BRL 49653 treatment, insulin stimulated glucose transport 2.8-fold. BRL 49653 did not alter the sensitivity of glucose transport to insulin. The increase in insulin responsiveness was accompanied by a 2.5-fold increase in the total tissue content of the glucose transporter GLUT4. Glucose transport in adipocytes from lean littermates was not altered by BRL 49653. To establish the contribution of changes in glucose transporter trafficking to the BRL 49653-mediated increase in insulin action, the cell-impermeant bis-mannose photolabel 2-N-[4-(1-azi-2,2,2-trifluoroethyl)benzoyl]-1,3-bis-(D-mannos++ +-4-yloxy) -2-[2-3H]-propylamine was used to measure adipocyte cell-surface-associated glucose transporters.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. I. Shulman and D. J. Mangelsdorf Retinoid X Receptor Heterodimers in the Metabolic Syndrome N. Engl. J. Med., August 11, 2005; 353(6): 604 - 615. [Full Text] [PDF]

				W. Verreth, D. De Keyzer, M. Pelat, P. Verhamme, J. Ganame, J. K. Bielicki, A. Mertens, R. Quarck, N. Benhabiles, G. Marguerie, et al. Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-{alpha} and Peroxisome Proliferator-Activated Receptor-{gamma} Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice Circulation, November 16, 2004; 110(20): 3259 - 3269. [Abstract] [Full Text] [PDF]

				K. T. Dalen, S. M. Ulven, K. Bamberg, J.-A. Gustafsson, and H. I. Nebb Expression of the Insulin-responsive Glucose Transporter GLUT4 in Adipocytes Is Dependent on Liver X Receptor {alpha} J. Biol. Chem., November 28, 2003; 278(48): 48283 - 48291. [Abstract] [Full Text] [PDF]

				C.-H. Lee, P. Olson, and R. M. Evans Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors Endocrinology, June 1, 2003; 144(6): 2201 - 2207. [Abstract] [Full Text] [PDF]

				K. Hallsten, K. A. Virtanen, F. Lonnqvist, H. Sipila, A. Oksanen, T. Viljanen, T. Ronnemaa, J. Viikari, J. Knuuti, and P. Nuutila Rosiglitazone but Not Metformin Enhances Insulin- and Exercise-Stimulated Skeletal Muscle Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes Diabetes, December 1, 2002; 51(12): 3479 - 3485. [Abstract] [Full Text] [PDF]

				B. M. Jucker, T. R. Schaeffer, R. E. Haimbach, T. S. McIntosh, D. Chun, M. Mayer, D. H. Ohlstein, H. M. Davis, S. A. Smith, A. R. Cobitz, et al. Normalization of Skeletal Muscle Glycogen Synthesis and Glycolysis in Rosiglitazone-Treated Zucker Fatty Rats: An In Vivo Nuclear Magnetic Resonance Study Diabetes, July 1, 2002; 51(7): 2066 - 2073. [Abstract] [Full Text] [PDF]

				N. Khandoudi, P. Delerive, I. Berrebi-Bertrand, R. E. Buckingham, B. Staels, and A. Bril Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-{gamma}, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury Diabetes, May 1, 2002; 51(5): 1507 - 1514. [Abstract] [Full Text] [PDF]

				T. P. Combs, J. A. Wagner, J. Berger, T. Doebber, W.-J. Wang, B. B. Zhang, M. Tanen, A. H Berg, S. O'Rahilly, D. B. Savage, et al. Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPAR{gamma} Agonists: A Potential Mechanism of Insulin Sensitization Endocrinology, March 1, 2002; 143(3): 998 - 1007. [Abstract] [Full Text] [PDF]

				M. Shintani, H. Nishimura, S. Yonemitsu, Y. Ogawa, T. Hayashi, K. Hosoda, G. Inoue, and K. Nakao Troglitazone Not Only Increases GLUT4 but Also Induces Its Translocation in Rat Adipocytes Diabetes, October 1, 2001; 50(10): 2296 - 2300. [Abstract] [Full Text]

				N. D. Oakes, P. G. Thalén, S. M. Jacinto, and B. Ljung Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability Diabetes, May 1, 2001; 50(5): 1158 - 1165. [Abstract] [Full Text]

				Y. Kanoh, G. Bandyopadhyay, M. P. Sajan, M. L. Standaert, and R. V. Farese Rosiglitazone, Insulin Treatment, and Fasting Correct Defective Activation of Protein Kinase C-{{zeta}}/{{lambda}} by Insulin in Vastus Lateralis Muscles and Adipocytes of Diabetic Rats Endocrinology, April 1, 2001; 142(4): 1595 - 1605. [Abstract] [Full Text]

				H. S. Ahuja, S. Liu, D. L. Crombie, M. Boehm, M. D. Leibowitz, R. A. Heyman, C. Depre, L. Nagy, P. Tontonoz, and P. J. A. Davies Differential Effects of Rexinoids and Thiazolidinediones on Metabolic Gene Expression in Diabetic Rodents Mol. Pharmacol., April 1, 2001; 59(4): 765 - 773. [Abstract] [Full Text]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]

				U. Edvardsson, M. Bergström, M. Alexandersson, K. Bamberg, B. Ljung, and B. Dahllöf Rosiglitazone (BRL49653), a PPAR{gamma}-selective agonist, causes peroxisome proliferator-like liver effects in obese mice J. Lipid Res., July 1, 1999; 40(7): 1177 - 1184. [Abstract] [Full Text]

				J. R. Zierath, J. W. Ryder, T. Doebber, J. Woods, M. Wu, J. Ventre, Z. Li, C. McCrary, J. Berger, B. Zhang, et al. Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer (PPAR{gamma} Agonist) Action Endocrinology, December 1, 1998; 139(12): 5034 - 5041. [Abstract] [Full Text] [PDF]

				L. S. Liu, H. Tanaka, S. Ishii, and J. Eckel The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes Endocrinology, November 1, 1998; 139(11): 4531 - 4539. [Abstract] [Full Text] [PDF]

				T.-Z. Su, M. Wang, D. L. Oxender, and A. R. Saltiel Troglitazone Increases System A Amino Acid Transport in 3T3-L1 Cells Endocrinology, March 1, 1998; 139(3): 832 - 837. [Abstract] [Full Text] [PDF]

				P. W. Young, D. R. Buckle, B. C. C. Cantello, H. Chapman, J. C. Clapham, P. J. Coyle, D. Haigh, R. M. Hindley, J. C. Holder, H. Kallender, et al. Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor gamma J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 751 - 759. [Abstract] [Full Text]

				A.-M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J.-C. Fruchart, C. Fievet, J. Auwerx, and B. Staels Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1756 - 1764. [Abstract] [Full Text]

				Y. Kanoh, G. Bandyopadhyay, M. P. Sajan, M. L. Standaert, and R. V. Farese Thiazolidinedione Treatment Enhances Insulin Effects on Protein Kinase C-zeta /lambda Activation and Glucose Transport in Adipocytes of Nondiabetic and Goto-Kakizaki Type II Diabetic Rats J. Biol. Chem., May 26, 2000; 275(22): 16690 - 16696. [Abstract] [Full Text] [PDF]

				H. Nishizawa, K. Yamagata, I. Shimomura, M. Takahashi, H. Kuriyama, K. Kishida, K. Hotta, H. Nagaretani, N. Maeda, M. Matsuda, et al. Small Heterodimer Partner, an Orphan Nuclear Receptor, Augments Peroxisome Proliferator-activated Receptor gamma Transactivation J. Biol. Chem., January 4, 2002; 277(2): 1586 - 1592. [Abstract] [Full Text] [PDF]